Clinical Trial · NCT06414902

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Overview

To learn if 18F-FAraG PET scans can find tumors in participants with esophageal cancer and predict a participant's response to treatment.

Sponsor

MD Anderson Cancer Center

Phase

Phase 1

Contacts

Steven Lin, MD (CONTACT)

shlin@mdanderson.org

(713) 563-8490

Steven Lin, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

Drug / Compound

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Eligibility

Female participants of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical
1. Participants must be ≥18 years of age
Ability to provide written informed consent in accordance with institutional policies
Participants with locally advanced esophageal cancer
Participants with untreated documented carcinoma of the esophagus that is \> 2 cm in patients who are going to receive systemic therapy concurrently with radiation as primary therapy are eligible

eGFR\<40 within 1 month prior to receiving 8F-FAraG
Pregnant or lactating females - Pregnant women are excluded from this study because 18F-FAraG PET agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with \[Agent\], breastfeeding should be discontinued if the mother is treated with \[Agent\]. These potential risks may also apply to other agents used in this study.
1. Body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
History of allergic reaction to intravenous contrast